Bright Minds Biosciences Inc. (DRUG )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DRUG
- Company Bright Minds Biosciences Inc.
- Price $38.49
- Changes Percentage 1445.78
- Change 36
- Day Low $2.49
- Day High $38.49
- Year High $38.49
- Year Low $0.93
- Market Cap $171,813,202
- Price Avg 50 EMA (D) $1.16
- Price Avg 200 EMA (D) $1.33
- Exchange NASDAQ
- Volume 98,035,273
- Average Volume 432,596
- Open $2.62
- Previous Close $2.49
- EPS -0.64
- PE -60.14
- Earnings Announcement 2024-11-27 12:00:00
- Shares Outstanding $4,463,840
Company brief: BRIGHT MINDS BIOSCIENCES INC. (DRUG )
- Healthcare
- Biotechnology
- Mr. Ian McDonald
- https://brightmindsbio.com
- CA
- N/A
- 03-22-2021
- CA10919W4056
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.